By Justin Petrone

A recent study by the Wellcome Trust Case Control Consortium has found that common copy number variants assessed by current array technology have little influence on common human diseases. In response to the findings, the researchers vowed to continue using CNV-typing array platforms in their research, while focusing more on rarer variants.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.